Company News »

Invitae Announces Completion of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire
Share on StockTwits
Published on

Invitae Corporation (NYSE:NVTA) , a genetic information company, announced today the closing of its initial public offering of 7,302,500 shares of common stock at an initial public offering price of $16.00 per share, which included 952,500 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock. Total gross proceeds from the offering were approximately $116.8 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Invitae. Invitae’s common stock is listed on the New York Stock Exchange under the symbol “NVTA.”

J.P. Morgan Securities LLC acted as the sole book-running manager for the offering. Cowen and Company, LLC and Leerink Partners LLC acted as co-managers.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 11, 2015. Copies of the final prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Invitae

Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic service comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics.

Share on StockTwits